These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 30799830)
1. Resistance profile of children and adolescents infected with HIV-1 in urban areas in Togo. Takassi OE; Salou M; Djadou KE; Agbéko F; Agbèrè D; Géraldo R; Dagnra A; Atakouma Y Med Sante Trop; 2018 Nov; 28(4):419-423. PubMed ID: 30799830 [TBL] [Abstract][Full Text] [Related]
2. High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo. Salou M; Dagnra AY; Butel C; Vidal N; Serrano L; Takassi E; Konou AA; Houndenou S; Dapam N; Singo-Tokofaï A; Pitche P; Atakouma Y; Prince-David M; Delaporte E; Peeters M J Int AIDS Soc; 2016; 19(1):20683. PubMed ID: 27125320 [TBL] [Abstract][Full Text] [Related]
3. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. Kebe K; Thiam M; Diagne Gueye NR; Diop H; Dia A; Signate Sy H; Charpentier C; Belec L; Mboup S; Toure Kane C AIDS Res Hum Retroviruses; 2013 Feb; 29(2):242-9. PubMed ID: 22860571 [TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
5. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632 [TBL] [Abstract][Full Text] [Related]
6. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. Bannister WP; Ruiz L; Cozzi-Lepri A; Mocroft A; Kirk O; Staszewski S; Loveday C; Karlsson A; Monforte Ad; Clotet B; Lundgren JD; AIDS; 2008 Jan; 22(3):367-76. PubMed ID: 18195563 [TBL] [Abstract][Full Text] [Related]
7. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171 [TBL] [Abstract][Full Text] [Related]
8. Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals. Babajide K; Ayemoba O; Terfa K; Ake J; Crowell TA; Adamu Y; Mohammed T; Okoye I; Odeyemi S; Crawford K; Hughes L; Akintunde E; Umar T; Hamm TE; Njoku OS Curr HIV Res; 2017; 15(2):146-151. PubMed ID: 28521719 [TBL] [Abstract][Full Text] [Related]
9. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293 [TBL] [Abstract][Full Text] [Related]
10. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370 [TBL] [Abstract][Full Text] [Related]
11. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. Steegen K; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; Variava E; MacLeod W; Sanne I; Stevens WS; Carmona S J Antimicrob Chemother; 2017 Jan; 72(1):210-219. PubMed ID: 27659733 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Puthanakit T; Jourdain G; Hongsiriwon S; Suntarattiwong P; Chokephaibulkit K; Sirisanthana V; Kosalaraksa P; Petdachai W; Hansudewechakul R; Siangphoe U; Suwanlerk T; Ananworanich J; HIV Med; 2010 Oct; 11(9):565-72. PubMed ID: 20345882 [TBL] [Abstract][Full Text] [Related]
13. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546 [TBL] [Abstract][Full Text] [Related]
14. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF; AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184 [TBL] [Abstract][Full Text] [Related]
15. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
16. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns. Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J Virol J; 2015 Nov; 12():187. PubMed ID: 26578099 [TBL] [Abstract][Full Text] [Related]
17. Virological response, HIV-1 drug resistance mutations and genetic diversity among patients on first-line antiretroviral therapy in N'Djamena, Chad: findings from a cross-sectional study. Adawaye C; Fokam J; Kamangu E; Alio HM; Chahad AM; Susin F; Moussa AM; Bertin TH; Tidjani A; Vaira D; Moutschen M BMC Res Notes; 2017 Nov; 10(1):589. PubMed ID: 29126456 [TBL] [Abstract][Full Text] [Related]
18. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda. Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608 [TBL] [Abstract][Full Text] [Related]
19. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy. Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129 [TBL] [Abstract][Full Text] [Related]
20. Virological response and resistance profiles after 18 to 30 months of first- or second-/third-line antiretroviral treatment: a cross-sectional evaluation in HIV type 1-infected children living in the Central African Republic. Charpentier C; Gody JC; Mbitikon O; Moussa S; Matta M; Péré H; Fournier J; Longo Jde D; Bélec L AIDS Res Hum Retroviruses; 2012 Jan; 28(1):87-94. PubMed ID: 21599597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]